FORQEZBI
Live / Allowed — Publication / registration review complete (as of 28 Aug 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 19 May 2026 filing date already counts against anyone who files later.
Record
- Serial number
- 99831775
- Mark type
- Stylized text
- Filed
- 19 May 2026
- Published for opposition
- 15 Sept 2026
- Attorney of record
- Christopher M. Hanes
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectives
Owner
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 09 Sept 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 21 Aug 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 14 Aug 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 14 Aug 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 14 Aug 2026 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
- 24 Jul 2026 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 24 Jul 2026 — LETTER OF SUSPENSION E-MAILED
- 24 Jul 2026 — SUSPENSION LETTER WRITTEN
- 22 Jul 2026 — ASSIGNED TO EXAMINER
- 19 May 2026 — APPLICATION FILING RECEIPT MAILED
- 19 May 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 19 May 2026 — NEW APPLICATION ENTERED